Lack of CD56 expression was reported to be associated with a poor prognosis in multiple myeloma (MM) patients treated with conventional chemotherapy. Aim of our retrospective study was to analyse whether CD56 expression on MM cells reveals as a prognostic factor in patients treated with high-dose chemotherapy. MM cells of 99 patients prior to treatment with high-dose chemotherapy were analysed for CD56 expression by flow cytometry. Multivariable analysis of event-free survival in these patients showed no statistically significant difference between the CD56 À (n ¼ 28) and the CD56 þ (n ¼ 71) group. The lack of CD56 expression on MM cells of these patients correlated significantly with the presence of translocation (11;14) (t(11;14)) (estimated correlation coefficient ¼ 0.655 95%, confidence interval (0.481; 0.779)). In summary, our results indicate that lack of CD56 expression on MM cells is not a prognostic marker in patients treated with high-dose chemotherapy, but is associated with t(11;14).
Introduction
Multiple myeloma (MM) still remains an incurable disease although high-dose melphalan followed by autologous stem cell transplantation (ABSCT) improved response rates. Complete remission rates up to 40%, as well as a prolonged disease-free survival, have been achieved with high-dose melphalan. 1 The high-dose melphalan treatment-related mortality is below 5%. 2 Because of the highly variable clinical course of the disease when classified according to Salmon and Durie, cytogenetic data as well as b2-microglobulin and serum albumin level were introduced to state the clinical outcome more precisely. The identification of prognostic factors for the clinical course of the disease and thus revealing risk groups is important.
CD56 mediates cell-cell and cell-matrix interactions. 3 Recent data indicate that loss in CD56 expression plays an essential role for the progression to tumour metastasis and increased malignancy of the tumour. 4, 5 CD56 was reported to be expressed on MM cells in 70-80% of the patients. [6] [7] [8] [9] Rawstron et al. 10 showed that the expression of CD56 is constant over the course of disease. Further data indicate that the expression of CD56 is a feature of MM cells that distinguishes them from monoclonal gammopathy of undetermined significance (MGUS), 11, 12 extramedullary plasmocytoma 13 and from plasma cell leukaemia, 14 indicating a more aggressive course of the disease in case of CD56 loss and an important role for CD56 for the capacity of MM cells to spread out of the bone marrow. 7, 15 Regarding the microenvironment, Barille et al. 16 showed that CD56 on MM cells is necessary for interactions between osteoblasts and MM cells in terms of triggering IL-6 secretion. Due to these pathophysiological functions, further clinical investigations were performed to clarify the role of CD56 in MM.
The lack of CD56 expression on MM cells was found to be associated with higher levels of b2-microglobulin, BenceJones proteinuria, renal insufficiency, thrombocytopaenia, plasmablastic morphology and a lower overall survival in 70 patients treated with conventional chemotherapy. 6 Recently, Chang et al. 17 analysed the role of CD56 expression on MM cells as a prognostic factor in MM patients treated by high-dose chemotherapy (n ¼ 107). They found no significant difference in terms of overall survival between the CD56 þ and CD56 À group, suggesting that melphalan-based high-dose chemotherapy and ABSCT may overcome the adverse influence of CD56-negative MM.
Cytogenetic abnormalities such as deletion of 13q14, translocation t(4;14) or t (11;14) have been associated with distinct subgroups in terms of prognosis of the disease. Tricot et al. 18 reported a poor prognosis in MM patients with alterations of chromosome 11, and Fonseca et al. 19 found MM cell clones with a t (11;14) to be a subset of MM in terms of prognosis. Pruneri et al. 20 showed that the t(11;14) is associated with an overexpression of cyclin D1. Like lack of CD56, t (11;14) is associated with an immature morphology of the MM cells, a poor prognosis after conventional and an improved event-free survival after high-dose chemotherapy. 6, 19, 21, 22 To evaluate the prognostic role of CD56 expression and its associations with cytogenetic abnormalities, we retrospectively analysed 99 patients with newly diagnosed MM. Patient characteristics are shown in Table 1 .
Materials and methods

Expression
Flow cytometry
Bone marrow was obtained from patients with MM for analysis of CD56 expression. Cells were stained with fluorescein isothiocyanate-labelled anti-CD138 (Milteny Biotec, Bergisch Gladbach, Germany), and R-phycoerythrin-labelled anti-CD56 (Becton Dickinson, Bioscience, Heidelberg, Germany) monoclonal antibody. Cells were counted using a flow cytometer (FACS Calibur, Becton Dickinson) and gated by their forward and side-scatter characteristics and CD138 expression. The cutoff for positive CD56 expression was set by analysis of CD56 expression in normal donors. Cutoff was set in this way that all CD138 þ cells from bone marrow of normal donors were negative for CD56 expression. CD56 expression in patients was defined as positive when 20% of the CD138 þ population expressed CD56 above the cutoff.
Molecular cytogenetics
Interphase fluorescent in situ hybridization analysis using probes for deletion 13q14 and t(11;14) was performed on cytospins of purified CD138-positive plasma cells. Slides were pre-treated with RNase and pepsin in accordance with standard protocols as published earlier 23 and fixed with formaldehyde. After dehydration using increasing concentrations of ethanol, cellular DNA was denaturated using formamide at 75 1C. DNA probes were denaturated separately and hybridized to the sample overnight at 37 1C. Microscopic analysis was performed using a DM 
Statistical analysis
The primary end point of this retrospective study was to analyse the event-free survival. The duration of event-free survival was calculated for all patients from the beginning of induction therapy and from ABSCT until progression of disease, death or the date the patient was last known to be in remission. Event-free survival times of patients being event free at the end of study were censored. In addition, allogeneic stem cell transplantation was regarded as censoring event.
The event-free survival was analysed by the AndersenGill formulation of the Cox proportional hazards model for counting processes. 24 ABSCT was regarded as timedependent intervention so that any patient would have one or two time intervals. The following covariates were included in the analysis: b2-microglobulin, albumin, del13q14, CD56 expression and ABSCT. All effects with P-values less than 0.05 were referred to as being statistically significant. Translocation t(11;14) was missing for 39 patients. Therefore separate regression models were analysed including and excluding t (11, 14) , respectively. The correlation between lack of CD56 expression and t (11;14) was estimated using the f coefficient of correlation of Yule including the corresponding 95% confidence interval. Patient characteristics were compared by Fisher's exact test for categorical variables and by the Mann-Whitney U-test for quantitative variables. All statistical tests were two-sided.
All statistical computations were performed by using R, version 2.4.1 (R Development Core Team, 2007).
Results and discussion
Multiple myeloma cells obtained from 99 patients prior to treatment were analysed for CD56 expression; myeloma cells of 71 patients were CD56
þ , myeloma cells of 28 patients were CD56 À . Of the 99 patients intented to treat by high-dose chemotherapy, 17 patients failed to get high-dose chemotherapy due to severe complications (three patients) or progressive disease (two patients from the CD56 À group, and 12 patients from the CD56 þ group). We analysed the response 3 months after first ABSCT and the event-free survival from the start induction therapy (Figure 1a) and from ABSCT (Figure 1b) . Three months after the first ABSCT, 6/25 of the CD56-negative patients were in CR, 17/25 in PR, 1/25 in MR and 1/25 had progressive disease (PD). In the CD56-positive group, 9/57 patients showed CR, 47/57 a PR, 1/57 a MR and 0/57 a PD (Table 1) . Only ABSCT and t (11, 14) were statistically significant in multivariable analysis of event-free survival (Tables 2a and b) .
Especially, we found no statistically significant effect of CD56 negativity, which is in contrast to Sahara et al. 6 who had shown a poor prognosis for patients with CD56
À MM cells. This might be due to the fact that most of our patients were treated with high-dose chemotherapy while patients in the Sahara study received conventional therapy. Eightytwo patients were treated with high-dose chemotherapy with 25 being CD56 À . The median event-free survival since ABSCT was 36.8 months for CD56
À patients and 28.9 months for CD56 þ patients (log rank test: P ¼ 0.63). Only five patients died during follow-up since ABSCT, three of them being CD56 À , so no statistical analysis of overall survival from ABSCT was performed.
We thus confirm the data from Chang et al. 17 proposing that high-dose chemotherapy can overcome the poor prognosis of MM patients without expression of CD56 on their MM cells. Figure 1a shows the Kaplan-Meier estimates of the event-free survival curves since the beginning of treatment according to CD56 negativity, while Figure 1b shows event-free survival since ABSCT. From 60 patients, cytogenetic data for t (11;14) were available. Eleven patients showed a t(11;14); 49 were negative for t (11;14) . Of the 14 patients with lack of CD56 expression, nine were t (11;14) positive. In contrast to 46 patients with CD56 positivity, only two showed a (Table 1 ). In accordance with Mateo et al., 25 we found a strong correlation between CD56 negativity of MM cells and t(11;14) (estimated correlation coefficient ¼ 0.66; 95% confidence interval (0.48; 0.78)).
Absence of CD56 expression and t (11;14) in MM patients are associated with an immature morphology of MM cells and results in a poor prognosis after conventional chemotherapy. 6, 21, 26 High-dose chemotherapy can overcome the poor prognosis of these patients, 17, 22, 27 suggesting that the lack of CD56 expression on myeloma cells and the translocation t (11;14) in these cells might define a biological subgroup of MM. Table 2 Andersen-Gill model for event-free survival (a) excluding t (11, 14) ; n ¼ 89 and (b) including t (11, 14) ; n ¼ 5 Abbreviation: ABSCT ¼ autologous stem cell transplantation.
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